GO
Loading...

Pharmaceuticals

More

  • TRENTON, N.J.— Drugmaker Bristol-Myers Squibb Co. said Thursday that an experimental combination of two hepatitis C drugs— its daclatasvir and Gilead Sciences Inc.' s blockbuster drug Sovaldi— cured hepatitis C in just 12 weeks in nearly all the patients, who also are infected with the HIV virus. David Wyles, an associate professor at University of...

  • O'Neill eyes up to $2 bln for fund to fight superbugs Thursday, 26 Feb 2015 | 12:18 PM ET

    LONDON, Feb 26- A global fund to speed development of new antibiotics to counter the growing threat of drug-resistant superbugs is likely to need up to $2 billion, the head of a review backed by the British government said on Thursday. Former Goldman Sachs chief economist Jim O'Neill has urged the establishment of an innovation fund to support research, arguing...

  • LAKE FOREST, Ill.— Shares of Akorn Inc. jumped Thursday after the generic-drug maker's fourth-quarter results and its outlook for 2015 surpassed Wall Street expectations. Akorn said its net income and revenue more than doubled after it acquired two other companies, Hi-Tech Pharmacal and VersaPharm, and had 14 drugs approved during the year.

  • Bayer R&D budget to increase  Thursday, 26 Feb 2015 | 6:00 AM ET

    Marijn Dekkers, CEO of Bayer, says the company plans to increase its R&D budget this year, after strong earnings.

  • Feb 26- Sanofi's new Toujeo diabetes drug has won U.S. regulatory approval but with wording on its label that analysts say could make marketing difficult. Sanofi shares were 1 percent lower at 88.20 euros by 1029 GMT. Sanofi bought some time with a patent infringement lawsuit filed last year against Eli Lilly and Co to keep a cheaper Lantus generic off the market...

  • *Sales of 5 key drugs seen at close to 4 bln eur in 2015. LEVERKUSEN, Germany, Feb 26- Germany's largest drugmaker Bayer said it expects underlying core earnings to increase by more than 10 percent this year, banking on a boost from new drugs such as stroke prevention pill Xarelto. The company is benefiting from a strong dollar in particular as North America accounts...

  • Feb 25- Cancer drug maker Pharmacyclics Inc is exploring a sale and has attracted interest from Johnson& Johnson and Novartis AG, Bloomberg reported. Pharmacyclics could fetch $17 billion- $18 billion from a possible sale, Bloomberg said on Wednesday, citing people familiar with the matter. A Pharmacyclics official said the company does not comment on rumors or...

  • Feb 25- Cancer drugmaker Pharmacyclics Inc is exploring a possible sale of the company and has attracted interest from Johnson& Johnson and Novartis AG, Bloomberg reported, citing people familiar the matter. Pharmacyclics could fetch $17- $18 billion from a possible sale, Bloomberg said on Wednesday. Sales of Imbruvica, which got U.S. Food& Drug Administration...

  • The products from South Korean firm Celltrion and its partners Hospira and Mundipharma will compete with Remicade, the original branded drug from Johnson& Johnson and Merck& Co.. Unlisted Mundipharma said on Wednesday that it is launching its biosimilar Remsima in Germany, Italy, Britain, the Netherlands, Belgium and Luxembourg, following expiry of relevant...

  • The products from South Korean firm Celltrion and its partners Hospira and Mundipharma will compete with Remicade, the original branded drug from Johnson& Johnson and Merck& Co.. Unlisted Mundipharma said on Wednesday that it is launching its biosimilar Remsima in Germany, Italy, Britain, the Netherlands, Belgium and Luxembourg, following expiry of relevant...

  • Feb 24- An experimental therapeutic vaccine from Danish drugmaker Bavarian Nordic helped significantly extend survival in patients with advanced prostate cancer, according to results of a small early-stage trial conducted by the U.S. National Cancer Institute. Patients were treated with the company's Prostvac vaccine, in addition to escalating doses of...

  • Vitamin Shoppe meets 4Q profit forecasts Tuesday, 24 Feb 2015 | 11:58 AM ET

    NORTH BERGEN, N.J. _ Vitamin Shoppe Inc. on Tuesday reported fourth-quarter profit of $11.6 million. The average estimate of analysts surveyed by Zacks Investment Research was also for earnings of 41 cents per share. Vitamin Shoppe expects full-year earnings to be $2.36 to $2.46 per share.

  • Medicago wins contract to develop Ebola treatments Tuesday, 24 Feb 2015 | 10:10 AM ET

    Feb 24- Canadian drugmaker Medicago said it received a contract from a U.S. federal agency to develop three different potential treatments for Ebola. The Biomedical Advanced Research and Development Authority has told the company that its anti-Ebola treatments should be efficient as Mapp Biopharmaceutical's ZMapp. The company said on Tuesday it would...

  • Watchdog group seeks FDA ban of antifungal tablets Tuesday, 24 Feb 2015 | 10:08 AM ET

    Public Citizen filed a petition Tuesday asking the FDA to ban ketoconazole tablets, which are used against hard-to-treat fungal infections. In July 2013 the FDA restricted ketoconazole's use to infections that do not respond to other drugs. Those findings were delivered at an agency workshop in January 2013, six months before the FDA decided to restrict the...

  • Merck grants free license for pediatric HIV drug Tuesday, 24 Feb 2015 | 3:02 AM ET

    TRENTON, N.J.— Drugmaker Merck& Co. has granted a free license allowing one of its HIV medicines to be made and sold inexpensively for use in young children in poor countries hard hit by the AIDS virus. The group, backed by the United Nations, works with brand-name drugmakers to find ways to make their HIV medicines still covered by patents available in developing...

  • Attorney General Eric Schneiderman sent letters Monday to four manufacturers, in Long Island, California and Utah, demanding detailed ingredient and quality control information on every herbal supplement they sell in New York state. The companies' products include the store-brand supplements Schneiderman ordered off the shelves at Walmart, Walgreen's,...

  • Takeda: What globalization means for us  Monday, 23 Feb 2015 | 6:44 PM ET

    Christophe Weber, president & COO of Takeda Pharmaceutical, says the research-based firm aims to be "present in all countries relevant for the pharmaceutical sector" via organic growth.

  • FDA approves Novartis drug for bone marrow cancer Monday, 23 Feb 2015 | 3:58 PM ET

    WASHINGTON— Federal health officials have approved a new drug from Swiss drugmaker Novartis to treat a form of bone marrow cancer. The Food and Drug Administration said Monday it approved Farydak for patients with multiple myeloma, which causes the buildup of plasma cells in the bone marrow. However, after the meeting Novartis submitted additional...

  • NEW YORK, Feb 23- U.S. stocks were down slightly in midday trading Monday as lower oil prices dragged down energy shares, pulling the Dow and S&P 500 off recent record levels. Oil prices fell, with WTI crude off $1.30 at $49.50 a barrel on oversupply concerns and a stronger dollar, pushing the S&P energy index down 0.6 percent. Investors were also reluctant to make big...

  • Feb 23- Rare disease drugmaker PTC Therapeutics Inc is exploring a potential sale amid takeover interest from several pharmaceutical companies, including Shire Plc and BioMarin Pharmaceutical Inc, according to people familiar with the matter. The stock of PTC Therapeutics, which has a market valuation of roughly $2 billion, rose as much as 25 percent to...